Bio-Techne (TECH) announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod’s NovoBody Duo molecules, a new class of AI-designed bispecific binding proteins.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target lowered to $68 from $72 at Evercore ISI
- Bio-Techne price target raised to $70 from $65 at UBS
- Bio-Techne price target lowered to $61 from $62 at Baird
- Bio-Techne Reports Q1 FY2026 Earnings with Strategic Focus
- Bio-Techne’s Earnings Call: Mixed Sentiment Amid Growth and Challenges